Sulfur Containing Patents (Class 536/54)
-
Publication number: 20030032620Abstract: The invention relates to a low molecular weight chondroitin sulphate compound having cosmetic activity, characterised more particularly by efficient incorporation in vitro of thymidine, glucosamine and leucine in fibroblast macromolecules of the human cutis. Local application of this compound stimulates fibroblast metabolism. The invention also relates to a method of preparing the said compound.Type: ApplicationFiled: July 25, 2001Publication date: February 13, 2003Inventors: Annie Landrein, Philippe Roy, Patrick Durand, Charles Delannoy
-
Patent number: 6518302Abstract: Compounds represented by general formula (I) wherein X represents OH or OSO3H; and R represents a substituent other than OH which allows, after leaving, the induction of unsaturated bonds into the 3- and 4-positions of 3,6-anhydrogalactose or its sulfated derivative, and/or a substituent showing a tissue-specific affinity.Type: GrantFiled: July 20, 2001Date of Patent: February 11, 2003Assignee: Takara Shuzo Co., Ltd.Inventors: Eiji Kobayashi, Tuo-Ping Li, Tatsuji Enoki, Takanari Tominaga, Hiroaki Sagawa, Ikunoshin Kato
-
Patent number: 6518410Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, &bgr;-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the &bgr;-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase &agr; inhibitor.Type: GrantFiled: September 10, 2001Date of Patent: February 11, 2003Assignee: Toyo Suisan Kaisha, Ltd.Inventors: Takayuki Yamazaki, Fumio Sugawara, Keisuke Ohta, Kazuyoshi Masaki, Kotaro Nakayama, Kengo Sakaguchi, Noriyuki Sato, Hiroeki Sahara, Tatsuya Fujita
-
Publication number: 20030023079Abstract: Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities are obtained by a process comprising the preparation of the K5 polysaccharide from Escherichia Coli, N-deacetylation/N-sulfation, C5 epimerisation, oversulfation, selective O-desulfation, selective 6-O sulfation and N-sulfation, in which said epimerisation is performed with the use of the enzyme glucuronosyl C5 epimerase in solution or immobilised in presence of specific divalent cations. New, particularly interesting compounds are obtained by controlling the reaction time in the O-desulfation step.Type: ApplicationFiled: December 18, 2000Publication date: January 30, 2003Inventors: Pasqua Oreste, Giorgio Zoppetti
-
Publication number: 20030013682Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds, where the U, R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic activity and are devoid of anticoagulant activity.Type: ApplicationFiled: July 25, 2002Publication date: January 16, 2003Inventors: Casu Banito, Torri Giangiacomo, Naggi Anna Maria, Giannini Giuseppe, Pisano Claudio, Penco Sergio
-
Patent number: 6495678Abstract: An immunosuppressant comprising Glucopyranose derivatives of the formula (I): wherein R is H, OH etc; G is —CH2CH(R1—R2)(R3—R4), in which R1 is a single bond, OCO-alkyl; R2, R4 is H, phenyl which may be substituted by halogen atoms etc.; R3 is alkylene; R5 is OCO-alkyl, R6 is H, phenyl which may be substituted by halogen atoms etc. or R5—R6 is OCO—Z-(dialkoxyphenyl); R7 is H, CH2OH etc; or non-toxic salts thereof as active ingredient. Glucopyranose derivatives of the formula (I) or non-toxic salts thereof possess an activity of immunosuppression, and being useful as the prevention and/or treatment of diseases caused by abnormal enhancement of immunity, e.g. allergic diseases, autoimmune diseases.Type: GrantFiled: November 6, 2000Date of Patent: December 17, 2002Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Gen-ichiro Soma, Nagashige Omawari
-
Patent number: 6486137Abstract: A mixture of linear oligosaccharides containing different numbers of repeating sulphated disaccharide units derived from L-iduronic acid (IdoA) and N-acetyl-D-galactosamine (Gal-NAc) and having the following characteristics (a) a molecular weight in the range of 1600-20000 for 90% or more of the mixture, (b) a sulphur content of 6.0-8.0% by weight, (c) a sulphate/carboxylate ratio of 1.2-1.6, (d) a disulphated disaccharide content of 20-60% by weight of the mono-sulphated disaccharide content, and (e) an antithrombin activity of 20-60 IU/mg. The mixture may be used as an antithrombotic agent and is prepared by depolymerisation of dermatan sulphate by periodate oxidation, followed by borohydride reduction and acid hydrolysis and then ion exchange fractionation.Type: GrantFiled: December 3, 1999Date of Patent: November 26, 2002Assignee: Leo Pharmaceutical Products Ltd. A/SInventors: Mons Lundqvist, Kristian Betton Johansen
-
Publication number: 20020169310Abstract: The Methods of the present invention prepare carrageenan products from processed seaweed material using shear stress treatment are disclosed. The carrageenan products comprise at least about 65% by weight of carrageenan and at least about 2% by weight of acid insoluble material. The carrageenan products of the present invention preferably have an onset of hydration below about 40*C and a color of greater than about 74 *L units. The carrageenan products of the present invention are useful as components in food products, such as, dairy products, meats, and dessert gels as well as non-food products, such as, toothpaste formulations, cosmetics, and paints.Type: ApplicationFiled: March 2, 2001Publication date: November 14, 2002Inventors: Albert G. Tsai, Linnea K.S. Ledwith, Robert Kopesky, Maurice Gerard Lynch, William Ross Blakemore, Peter J. Riley
-
Patent number: 6444795Abstract: 1-O-(2-propenyl)-6-O-sulfonylpyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or substituted silyl group, and R4 represents an alkylsulfonyl or arylsulfonyl group.Type: GrantFiled: October 11, 2000Date of Patent: September 3, 2002Assignee: Toyo Suisan Kaisha, Ltd.Inventors: Takayuki Yamazaki, Fumio Sugawara, Keisuke Ohta, Kazuyoshi Masaki, Kotaro Nakayama, Kengo Sakaguchi
-
Patent number: 6395886Abstract: 1-O-(2-propenyl)-6-deoxy-6-carbonylthiopyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or a substituted silyl group, and R5 represents a hydrogen atom, or an alkyl or aryl group.Type: GrantFiled: October 11, 2000Date of Patent: May 28, 2002Assignee: Toyo Suisan Kaisha, Ltd.Inventors: Takayuki Yamazaki, Fumio Sugawara, Keisuke Ohta, Kazuyoshi Masaki, Kotaro Nakayama, Kengo Sakaguchi
-
Publication number: 20020062019Abstract: Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.Type: ApplicationFiled: September 12, 2001Publication date: May 23, 2002Inventors: Pasqua Oreste, Giorgio Zoppetti
-
Publication number: 20020062020Abstract: A method for producing a S-nitrosylated species is provided. The method comprises: (a) providing a deoxygenated, alkaline aqueous solution comprising a thiol and a nitrite-bearing species; (b) acidifying the solution by adding acid to the solution while concurrently mixing the solution (e.g., by vigorously stirring the solution) to produce the S-nitrosylated species; and (c) isolating the S-nitrosylated species. The nitrite-bearing species can be, for example, an inorganic nitrite, such as an alkali metal nitrite, or an organic nitrite, such as an alkyl nitrite (e.g., ethyl nitrite, amyl nitrite, isobutyl nitrite or t-butyl nitrite). The thiol is preferably a thiol-containing polysaccharide, a thiol-containing lipoprotein, a thiol-containing amino acid or a thiol-containing protein, and more preferably a thiol-containing polysaccharide such as thiolated cyclodextrin. In many preferred embodiments, the S-nitrosylated species is insoluble in the acidified solution, precipitating upon formation.Type: ApplicationFiled: January 14, 2002Publication date: May 23, 2002Inventors: Robert A. Herrmann, David Knapp
-
Publication number: 20020061562Abstract: The invention provides an isolated polypeptide encoding a corneal N-acetylglucosamine-6-sulfotransferase (GlcNAc6ST) or active fragment thereof, where the GlcNAc6ST or active fragment thereof catalyzes sulfation of keratan sulfate. The present invention also provides a method of treating a subject with macular corneal dystrophy. The method includes the steps of administering to the subject an effective amount of an agent that increases expression or activity of a GlcNAc6ST, whereby the amount of sulfated keratan sulfate in the cornea of the subject is elevated. A method of the invention can be used to treat macular corneal dystrophy type I or type II.Type: ApplicationFiled: August 9, 2001Publication date: May 23, 2002Inventors: Michiko N. Fukuda, Tomoya O. Akama
-
Publication number: 20020034769Abstract: A complex of a water-soluble polymer containing hydrophobic regions and native sulfatide is disclosed. The complex may be used in assaying methods.Type: ApplicationFiled: June 15, 2001Publication date: March 21, 2002Inventors: Karsten Buschard, Pam Fredman, Jan-Eric Mansson
-
Publication number: 20020032158Abstract: The present invention is a compound of general formula (I) or a pharmaceutically acceptable salt of, 1Type: ApplicationFiled: June 12, 2001Publication date: March 14, 2002Applicant: KOTOBUKI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Tomiyama, Takashi Yanagisawa, Masayuki Nimura, Atsushi Noda, Tsuyoshi Tomiyama
-
Publication number: 20020022602Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure 1Type: ApplicationFiled: July 11, 2001Publication date: February 21, 2002Applicant: American Home Products CorporationInventor: Paul J. Dollings
-
Publication number: 20020015961Abstract: A hydrocarbyldithiomethyl-modified compound of the Formula:Type: ApplicationFiled: September 12, 2001Publication date: February 7, 2002Inventor: Marek Kwiatkowski
-
Publication number: 20010031752Abstract: The invention relates to substituted 8,8a-dihydro-3aH-indeno[1,2-d]thiazoles and to their physiologically acceptable salts and physiologically functional derivatives.Type: ApplicationFiled: February 23, 2001Publication date: October 18, 2001Inventors: Gerhard Jaehne, Hans-Jochen Lang, Matthias Gossel, Martin Bickel
-
Patent number: 6274144Abstract: A method for depolymerizing polysaccharides containing into saccharide fragments using ozonolysis is described.Type: GrantFiled: January 21, 2000Date of Patent: August 14, 2001Assignee: The Brigham and Women's Hospital, Inc.Inventors: Ying Wang, Rawle I. Hollingsworth, Dennis L. Kasper
-
Patent number: 6262255Abstract: Non-immunogenic biocompatible macromolecular sheet composition are formed from a cellulosic membrane, a binding moiety having a plurality of functional groups, and a glycosaminoglycan (GAG). The binding moiety has the formula of R1—X—R2 wherein R1 and R2 are the same or different. The binding moiety, through functional groups binds the cellulosic membrane with the glycosaminoglycan. R1 is covalently bound to a carbon or an oxygen of the cellulosic membrane. R2 is covalently bound to a carbon, an oxygen, or a nitrogen of the glycosaminoglycan. The binding moiety can be bis-oxyrane, butanediol-diglycidyl ether (BDE), or divinyl sulfone. The cellulosic membrane can be a cellulosic membrane, partially acetylated cellulose and a copolymer of hydroxyethyl-methacrylate with methyl methacrylate, abbreviated as HEMA-MMA. The non-immunogenic biocompatible macromolecular sheet composition can be formed into a pouch to encapsulate cells, tissues, pharmaceuticals, or biological metabolic products.Type: GrantFiled: April 5, 1995Date of Patent: July 17, 2001Assignee: BIOMM, Inc.Inventor: Marcos Mares-Guia
-
Patent number: 6225450Abstract: The invention describes a new method to sequence DNA. The improvements over the existing DNA sequencing technologies are high speed, high throughput, no electrophoresis and gel reading artifacts due to the complete absence of an electrophoretic step, and no costly reagents involving various substitutions with stable isotopes. The invention utilizes the Sanger sequencing strategy and assembles the sequence information by analysis of the nested fragments obtained by base-specific chain termination via their different molecular masses using mass spectrometry, as for example, MALDI or ES mass spectrometry. A flirter increase in throughput can be obtained by introducing mass-modifications in the oligonucleotide primer, chain-terminating nucleoside triphosphates and/or in the chain-elongating nucleoside triphosphates, as well as using integrated tag sequences which allow multiplexing by hybridization tag specific probes with mass differentiated molecular weights.Type: GrantFiled: June 7, 1995Date of Patent: May 1, 2001Assignee: Sequenom, Inc.Inventor: Hubert Köster
-
Patent number: 6162797Abstract: Derivatives of the K5 polysaccharide having anticoagulant activity higher than heparin, obtained by a process including the steps of reacting: with an organic base a solution of K5 polysaccharide N-deacetylated, N-sulfated and epimerized at least to an iduronic acid content of 50% treating with a sulfating agent to obtain the N-resulfation of the possible N-desulfated groups.Type: GrantFiled: November 6, 1998Date of Patent: December 19, 2000Assignee: Inalco S.p.A.Inventors: Giorgio Zoppetti, Pasqua Oreste, Giovanni Cipolletti
-
Patent number: 6136790Abstract: The invention relates to carbohydrate mimetics, which inhibit the binding of selectin to carbohydrate ligands, of the formula I ##STR1## excluding the compounds sialyl-Lewis-X and -A and their derivatives which, instead of an N-acetyl group, carry the substituents N.sub.3, NH.sub.2 or OH or which, instead of fucose, carry glycerol,and pharmaceutical compositions and diagnostic agents containing these derivatives, and methods for using these pharmaceutical compositions and diagnostic agents.Type: GrantFiled: July 28, 1997Date of Patent: October 24, 2000Assignee: Glycorex ABInventors: Alexander Toepfer, Gerhard Kretzschmar, Eckart Bartnik, Dirk Seiffge
-
Patent number: 6121430Abstract: New glucose-based surfactants and methods of their synthesis are described. The surfactants are synthesized through the preparation of an intermediate glucose 4,6-cyclic sulfate. The surfactants are economical to prepare and have excellent surface-active properties.Type: GrantFiled: April 23, 1999Date of Patent: September 19, 2000Assignee: University of Iowa Research FoundationInventors: Robert J. Linhardt, Helene G. Bazin
-
Patent number: 6106866Abstract: A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an anti tumor drug and may be taxol, a peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9% (w/w) and with selective oligosaccharide oversulfation.Type: GrantFiled: July 31, 1995Date of Patent: August 22, 2000Assignee: Access Pharmaceuticals, Inc.Inventor: David F. Ranney
-
Patent number: 6087339Abstract: Disclosed are novel saccharide derivatives which inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo. Additionally, disclosed are compounds which inhibit binding of enterovirulent organisms (e.g., bacteria, virus, fungi, and the like), such as Vibrio cholerae and enterotoxigenic strains of Escherichia coli, to their cell surface receptors.Type: GrantFiled: November 14, 1997Date of Patent: July 11, 2000Assignee: Synsorb Biotech, Inc.Inventor: Ole Hindsgaul
-
Patent number: 6084081Abstract: A novel fluorine-containing Lewis X derivative represented by the following formula (I): ##STR1## wherein R represents hydrogen, a hydroxyl-protective group, --PO(OH).sub.2, --SO.sub.3 H or sialylate;R.sup.1 represents hydrogen, hydroxyl, aliphatic acyloxy, aromatic acyloxy, lower alkylthio, optionally substituted phenylthio, lower alkoxy, branched long chain alkoxy, optionally substituted phenylmethoxy or sphingosinyl, R.sup.10 represents hydrogen or --O--C--(.dbd.NH)CCl.sub.3 ; provided that when R.sup.10 is --O--C--(.dbd.NH)CCl.sub.3, R.sup.9 is hydrogen;R.sup.2 and R.sup.3 are the same or different and independently represent hydrogen, aliphatic acyl, aromatic acyl or optionally substituted phenylmethyl; andR.sup.4 represents hydroxyl, aliphatic acyloxy, aromatic acyloxy, aliphatic acylamino or aromatic acylamino.Type: GrantFiled: May 6, 1999Date of Patent: July 4, 2000Assignee: Daikin Industries, Ltd.Inventors: Yutaka Ohira, Takao Iida
-
Patent number: 6034140Abstract: The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides and polyethers, and to the resulting compositions. The polymers are associated with each other, and are then either dried or are used as fluids. Bioresorbable, bioadhesive, anti-adhesion compositions are useful in surgery to prevent the formation of post-surgical adhesions. The compositions are designed to breakdown in-vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aqueous solutions. The anti-adhesion, bioadhesive, bioresorptive, antithrombogenic and physical properties of such membranes can be varied as needed by carefully adjusting the pH of the polymer casting solutions, polysaccharide composition, the polyether composition, or by conditioning the membranes prior to surgical use.Type: GrantFiled: February 13, 1998Date of Patent: March 7, 2000Assignee: FzioMed, Inc.Inventors: Herbert E. Schwartz, John M. Blackmore
-
Patent number: 5972907Abstract: Compounds which bind to selectin receptors and thus may modulate the course of inflammation, cancer and related processes by intervening with cell-cell adhesion events. Further, such compounds can be used for identification and analysis of such receptors. In this regard the invention is directed to compounds of formula (I). ##STR1## wherein R.sup.1 is independently H, alkyl, aryl, an aryl alkyl, alkenyl or one or more additional saccharide residues; R.sup.2 =H or OH provided that when R.sup.2 is H, R.sup.3 is OH; R.sup.3 =H or OH provided that when R.sup.3 is H, R.sup.2 is OH; X=H, SO.sub.3.sup.- or PO.sub.4.sup.- ; Y is independently H, OH, OR.sup.4 or NHCOR.sup.4, wherein R.sup.4 is alkyl, and Z is an organic acid residue. .alpha.-L-Fucose residue can be modified or replaced with suitable bioisosters or a different saccharide residue such as D-mannose. Modification of L-fucose may include replacement of each or all of the hydroxyl groups with H or OR' wherein R' can be methyl, ethyl or allyl groups.Type: GrantFiled: October 31, 1997Date of Patent: October 26, 1999Assignee: Health Research, Inc.Inventors: Khushi L. Matta, Rakesh K. Jain
-
Patent number: 5948405Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.Type: GrantFiled: December 18, 1997Date of Patent: September 7, 1999Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Armando Cedro, Roberto Porta, Franco Cattaneo, Fabio Trento, Laura Ferro, Ennio Lanzarotti
-
Patent number: 5925626Abstract: Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections.Type: GrantFiled: June 6, 1995Date of Patent: July 20, 1999Assignee: Fidia S.p.A.Inventors: Francesco della Valle, Aurelio Romeo
-
Patent number: 5922690Abstract: A method of inhibiting thrombin generation and of inhibiting complement activation by using a dermatan sulfate having at least 2 sulfate groups per disaccharide obtained by chemical sulfation of native dermatan sulfate. The resulting dermatan sulfate having an average molecular weight from about 5000 to 35000 Daltons is characterized by (i) a high content of L-iduronic->4,6-di-O-sulfated N-acetyl-D-galactosamine residues, and (ii) a specific heparin cofactor II-mediated anti-thrombin activity, depending on average molecular weight, between about 25 to 125 U/mg.Type: GrantFiled: February 6, 1997Date of Patent: July 13, 1999Inventors: Cornelius L. Van Gorp, Stephanie J. Brister, Michael R. Buchanan, Robert J. Linhardt
-
Methods of using low molecular weight heparins for prevention or treatment of pathological processes
Patent number: 5908837Abstract: The present invention relates to pharmaceutical compositions for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: November 7, 1997Date of Patent: June 1, 1999Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz -
Patent number: 5837695Abstract: The present invention relates to a unique fluorescently labeled Chlamydial antigen. This fluorescently labeled Chlamydial antigen is useful in immunoassay-type formatted systems for the detection of antibodies to Chlamydia or unlabeled Chlamydia antigens.Type: GrantFiled: August 22, 1996Date of Patent: November 17, 1998Assignee: Becton Dickinson and CompanyInventor: J. Bruce Pitner
-
Patent number: 5831077Abstract: The present invention consists in methods of preparing sugar derivatives either in isolation or from glycopeptides or glycoproteins. The methods comprise producing sugar hydrazones, sugar pyrazoles, glycosylpyrazones, azoglycan dyes and hydrazoglycan dyes. The present invention also relates to the removal of O-glycans from glycopeptides or glycoproteins, immobilizing reducing sugars onto solid supports and methods to obtain sugars from a glycopeptide or glycoprotein comprising subjecting the glycopeptide or glycoprotein to solid phase Edman degradation followed by separating and characterizing the sugars.Type: GrantFiled: September 23, 1996Date of Patent: November 3, 1998Inventors: John William Redmond, Nicolle Hannah Packer, Andrew Arthur Gooley, Keith Leslie Williams, Michael Batley, Warren Charles Kerr, Anthony Pisano, Helen Joan Tweeddale, Catherine Anne Cooper
-
Inhibitors of .beta.-glucuronidase and their use in the treatment of carcinamatosis and inflammation
Patent number: 5817800Abstract: Compounds of the formulae I and II ##STR1## are suitable for the suppression of tumor growth and of tumor metastasis.Type: GrantFiled: August 1, 1997Date of Patent: October 6, 1998Assignee: Hoechst AktiengesellschaftInventors: Klaus Bosslet, Jorg Czech, Andrea Vasella, Roland Hoos -
Patent number: 5808050Abstract: Non-immunogenic biocompatible macromolecular sheet composition are formed from a cellulosic membrane, a binding moiety having a plurality of functional groups, and a glycosaminoglycan (GAG). The binding moiety has the formula of R.sup.1 --X--R.sup.2 wherein R.sup.1 and R.sup.2 are the same or different. The binding moiety, through functional groups binds the cellulosic membrane with the glycosaminoglycan. R.sup.1 is covalently bound to a carbon or an oxygen of the cellulosic membrane. R.sup.2 is covalently bound to a carbon, an oxygen, or a nitrogen of the glycosaminoglycan. The binding moiety can be bis-oxyrane, butanediol-diglycidyl ether (BDE), or divinyl sulfone. The cellulosic membrane can be a cellulosic membrane, partially acetylated cellulose and a copolymer of hydroxyethyl-methacrylate with methyl methacrylate, abbreviated as HEMA-MMA.Type: GrantFiled: April 5, 1995Date of Patent: September 15, 1998Assignee: BIOMM, Inc.Inventor: Marcos Mares-Guia
-
Patent number: 5801162Abstract: Dermatan sulfate compositions having certain characteristics have been found to have thrombolytic activity. Dermatan sulfate combined with tissue plasminogen activator (t-PA) enhances the thrombolytic activity of t-PA. Antithrombotic compositions containing dermatan sulfates can be used for treating various thrombotic diseases.Type: GrantFiled: August 28, 1995Date of Patent: September 1, 1998Assignee: Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation)Inventors: Akikazu Takada, Junichi Onaya, Mikio Arai, Satoshi Miyauchi, Mamoru Kyogashima, Keiichi Yoshida
-
Patent number: 5795869Abstract: Semisynthetic analogues of gangliosides selected from the group consisting of N-sulfo-, N-hydrocarbyl-sulfonyl- and N-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N'-acyl derivatives thereof, N'-sulfo-, N'-hydrocarbylsulfonyl- and N'-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N-acyl derivatives thereof, N,N'-di or polysulfo-N,N'-di- or poly-lyso-gangliosides, N,N'-di- or polyhydrocarbylsulfonyl-N,N'-di- or poly-lyso-gangliosides and N,N'-di- or polyhydrocarbyloxy-N,N'-di- or poly-lyso-gangliosides, and functional derivatives thereof, and salts of these compounds, have protective activity against neurotoxicity induced by excitatory amino acids and are foreseen to be used in therapy in the nervous system and in modulating of the expression of determinants such as CD.sub.4 on the surface of human cells in the immune system.Type: GrantFiled: November 2, 1995Date of Patent: August 18, 1998Assignee: Fidia S.p.A.Inventors: Aurelio Romeo, Gunter Kirschner, Carlo Chizzolini, Hari Manev, Laura Facci
-
Patent number: 5792842Abstract: A ganglioside GM3 derivative having a fluorine atom at the 9-position of sialic acid represented by the formula: ##STR1## wherein R is an aliphatic lower acyl group, R.sup.1 is a hydrogen atom or a lower alkyl group, R.sup.2 to R.sup.5 represent independently of one another a hydrogen atom, an aliphatic lower acyl group or an aromatic acyl group, R.sup.11 is an straight or branched, saturated or unsaturated aliphatic hydrocarbon group having 1 to 30 carbon atoms, and n is an integer of 0 to 20, provided that when R.sup.1 is a hydrogen atom, R.sup.2 to R.sup.5 are hydrogen atoms, or when R.sup.1 is a lower alkyl group, R.sup.2 to R.sup.5 are each an aliphatic lower acyl group or an aromatic acyl group, and intermediates therefor. This compound is useful as an agent for preventing infection of the influenza virus, an agent for preventing proliferation and metastasis of the cancer cells, etc.Type: GrantFiled: April 16, 1996Date of Patent: August 11, 1998Assignee: Daikin Industries Ltd.Inventors: Takao Iida, Yutaka Ohira
-
Patent number: 5783570Abstract: The present invention relates to an organic solvent-soluble mucopolysaccharide consisting of an ionic complex of at least one mucopolysaccharide (preferably heparin or heparin derivative) and a quaternary phosphonium, an antibacterial antithrombogenic composition comprising said organic solvent-soluble mucopolysaccharide and an organic polymer material, an antibacterial antithrombogenic composition comprising said organic solvent-soluble mucopolysaccharide and an antibacterial agent (preferably inorganic antibacterial agent such as silver zeolite), and to a medical material comprising said organic solvent-soluble mucopolysaccharide.Type: GrantFiled: December 23, 1996Date of Patent: July 21, 1998Assignee: Toyo Boseki Kabushiki KaishaInventors: Hideyuki Yokota, Masakazu Tanaka, Masahiro Seko, Noriko Monden, Susumu Arimori, Shigeji Konagaya
-
Patent number: 5753631Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.Type: GrantFiled: May 31, 1995Date of Patent: May 19, 1998Assignee: Cytel CorporationInventors: James C. Paulson, Mary S. Perez, Federico C. A. Gaeta, Robert M. Ratcliffe
-
Patent number: 5739304Abstract: Water-soluble polysaccharides which containa) substituents selected from the group consisting of alkyl, hydroxyalkyl, carboxyalkyl and sulfoalkyl,b) N,N-disubstituted aminoalkyl groups,are prepared by alkylation of a polysaccharide in the presence of a base with one or more alkylation reagents, selected from the group consisting of compounds transferring alkyl groups, compounds transferring hydroxyalkyl groups, compounds transferring carboxyalkyl groups and compounds transferring sulfoalkyl groups, and also with an N,N-disubstituted amino-alkylsulfuric acid ester. The modified polysaccharides are used in paper production and waste-water purification and also in cosmetics.Type: GrantFiled: December 22, 1995Date of Patent: April 14, 1998Assignee: Hoechst AGInventors: Reinhard Doenges, Rudolf Ehrler, Andreas Schrell
-
Patent number: 5714598Abstract: A sulfated acid amide having heparin-like properties of the formula:(R.sub.1)--NH--R--NH--(R.sub.1)where R.sub.1 is a di-, tri- or tetra-saccharide acid selected from cellobiose, cellotriose, cellotetrose, maltose, maltotriose and maltotetrose or mixtures thereof, and R is an alkylene of from 3 to 12 carbons, and is optionally substituted with one or more hydroxyls.Type: GrantFiled: October 4, 1995Date of Patent: February 3, 1998Assignee: Reliable Biopharmaceutical CorporationInventor: Joseph A. Toce
-
Patent number: 5705493Abstract: Oligosaccharides derived from natural or supersulphated GAGS or their mixtures, with a heparin content less than 1% by wt. having average molecular weight between 2,500 and 15,000 dalton, at least 50% by wt. of said oligosaccharide having a molecular weight in the +20% range in respect of the average molecular weight, providing an exceptional bioavailability and an antithrombin activity equal or higher than the starting GAGS.Type: GrantFiled: June 6, 1995Date of Patent: January 6, 1998Assignee: Mediolanum Farmaceutici S.p.A.Inventor: Gianni Ferrari
-
Patent number: 5693623Abstract: Topical Preparations for the treatment of acne and acneiform dermatitis containing as active principle therapeutically active quantities of N,N'bis (2-hydroxyethyl) nonandiamide together with dermatansulfate lithium salt, having molecular weight ranging from 2000 to 7000, combined with suitable excipients and/or diluents.Type: GrantFiled: June 6, 1995Date of Patent: December 2, 1997Assignee: LifeGroup S.p.A.Inventors: Francesco della Valle, Roberto Cerini, Gabriella Calderini
-
Patent number: 5686431Abstract: The present invention relates to methods for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular Weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: June 1, 1995Date of Patent: November 11, 1997Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz
-
Patent number: 5677285Abstract: Provided are new derivatives of neuraminic acid of formula (I), where Ac represents an acyl residue of an aliphatic, araliphatic, aromatic, alicyclic, or heterocyclic carboxylic acid, including carboxylic amides, their 2-hydrocarbyl-glycosides, and their peracylated derivatives at the hydroxy groups of both these series of amides. These compositions are therapeutically useful in providing a protective effect against the neurotoxicity induced by excitatory amino acids, and can therefore be used in therapies of the central nervous system.Type: GrantFiled: April 26, 1995Date of Patent: October 14, 1997Assignee: Fidia S.P.A.Inventors: Aurelio Romeo, Gunter Kirschner, Hari Manev, Martino Trimarco, Gino Toffano
-
Patent number: 5646205Abstract: An ionomer for an ion complex membrane useful for the separation of water-organic solvent by osmosis or low pressure osmosis as well as by pervaporation and a method for producing ion complex membrane therefrom are disclosed. The ionomer for producing ion complex membrane can be prepared by heat polymerization of an alkyl compound having pyridyl groups such as 1,3-di(4-pyridyl) propane at both terminal ends with a dihaloalkane compound such as dibromooctane and dichloroheptane having two halogen atoms at both terminal ends or with one or two halogen atoms affixed to intermediate carbon atoms in a polar solvent such as acrylonitrile. An ion complex membrane can be produced by preparing a membrane of a polycation or polyanion in a solution casting method and dipping the membrane in a solution of polycation or polyanion for 24 hours to give an ion complex membrane. This ion complex membrane may be a single membrane or composite membrane. Composite membrane includes a plain membrane and a hollow fiber membrane.Type: GrantFiled: June 14, 1995Date of Patent: July 8, 1997Assignee: Korea Research Institute of Chemical TechnologyInventors: Kew Ho Lee, Jung Hoon Kim, Jong Geon Jegal
-
Patent number: RE36385Abstract: This invention relates to glucopyranose compounds of formula (I) and (IA) ##STR1## and the non-toxic salts thereof wherein the substituents are as defined herein. Such materials possess enhancing activity of cellular immunity (e.g. mitogenic activity) to living tissue and therefore are useful as anti-tumor agents.Type: GrantFiled: May 20, 1993Date of Patent: November 9, 1999Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Masaaki Toda, Yutaro Sasaki, Katsuichi Shimoji